Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
‘The Price of Business’: Discussing the Latest Inflation Report

‘The Price of Business’: Discussing the Latest Inflation Report

Jul 12, 2023 | Interviews

On July 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the latest inflation report. What could be behind the significant drop?

Alex Brill Interviewed on the Future of the Adalimumab Market 

Alex Brill Interviewed on the Future of the Adalimumab Market 

Jun 28, 2023 | News

MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1. 

Taking Stock of the Humira Biosimilars Market

Taking Stock of the Humira Biosimilars Market

Jun 26, 2023 | Commentary

In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.

MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals

MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals

Jun 14, 2023 | Interviews

Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy. 

Analyzing the Build It in America Act: Proposals for Business Tax Reform

Analyzing the Build It in America Act: Proposals for Business Tax Reform

Jun 12, 2023 | Op-Eds

Last week, the House Committee on Ways and Means released three tax bills, and this week the Committee will meet to consider these measures.

Page 4 of 57« First«...23456...»Last »
  • Analysis (43)
  • Books (3)
  • Commentary (6)
  • Events (17)
  • Interviews (55)
  • News (54)
  • Op-Eds (84)
  • Press Releases (4)
  • Testimony (21)
  • Patent Thicket Remedies
    Patent Thicket RemediesDecember 7, 2023
  • US Tax Policy Israel-Hamas Conflict
    Don’t Mix US Tax Administration Policy with the Israel-Hamas ConflictNovember 2, 2023
  • Economics of Delinking PBM Compensation
    The Economics of “Delinking” PBM CompensationNovember 2, 2023
  • Leave the Tax Code Alone
    The Supreme Court Should Leave the Tax Code AloneOctober 24, 2023
  • Implications of Cannabis Legalization
    Implications of Cannabis Legalization for the US Federal BudgetOctober 24, 2023
  • Amicus Brief in Moore v. United States
    Amicus Brief in Moore v. United StatesOctober 24, 2023
  • Biosimilars Keys to Success
    Biosimilars – Keys to Success in the Pharmacy BenefitOctober 3, 2023
  • Regulatory Uncertainty for ESOPs
    New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee OwnershipOctober 2, 2023
  • PBMs in US Drug Pricing Debate
    MGA Releases White Paper on Role of PBMs in US Drug Pricing DebateSeptember 26, 2023
  • Unintended Consequences of Limiting PBMsSeptember 26, 2023
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact